The Centers for Medicare & Medicaid Services has released Medicare payment codes effective Feb. 11 for administering the monoclonal antibody bebtelovimab, effective against the omicron COVID-19 variant. The Food and Drug Administration last week authorized the drug to treat outpatients at risk of progressing to severe disease or hospitalization. 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services Feb. 23 announced the development of its Medicare App Library. As part of the agency’s Health Technology…
Headline
The Congressional Budget Office has projected that the Hospital Insurance Trust Fund will have sufficient funds to pay full benefits until 2040 — 12 years…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
A JAMA study published Feb. 18 found that 10% of Medicare Advantage beneficiaries — approximately 2.9 million — have needed to find other health coverage for…
Headline
The AHA Feb. 17 submitted a comment letter responding to the Centers for Medicare & Medicaid Services’ proposed rule that would prohibit hospitals…
Headline
The Senate Special Committee on Aging held a hearing Feb. 11 on issues impacting physician burnout. The AHA provided a statement for the hearing and urged…